Key Points Verastem Oncology reported $25.1 million in Q2 2026 net product revenue from AVMAPKI FAKZYNJA CO-PACK, up 34% sequentially from $18.7 million in Q1….
Ahead of Nuvation Bio’s (NYSE: NUVB) second-quarter results, investors were looking for evidence that the company’s strong first quarter represented the beginning of a sustainable…
Key Points Citius Oncology, Inc. reports accelerating commercial momentum for LYMPHIR, its FDA‑approved treatment for cutaneous T‑cell lymphoma (CTCL). New U.S. institutions ordering LYMPHIR rose…
Key Points BriaCell Therapeutics Corp. received FDA clearance to begin a clinical study of Bria-PROS in prostate cancer. The company is developing Bria-PROS as a…
Corbus Pharmaceuticals received FDA clearance to start its TEMPO‑1 registrational trial. Registrational studies are designed to provide the pivotal data needed to support a future…
bioAffinity Technologies (Nasdaq: BIAF) is highlighting a new clinical framework that explains where CyPath® Lung may fit in the evaluation of pulmonary nodules and ongoing…
July 17, 2026
Illuccix Japan Study Hits Full Enrollment as Telix Moves Closer to Prostate Cancer Imaging Approval
Telix Pharmaceuticals (NASDAQ: TLX) has hit a key clinical milestone, finishing patient enrollment in its Phase 3 Illuccix Japan study of TLX591‑Px for prostate cancer…
Telix Pharmaceuticals (NASDAQ: $TLX) and St Vincent’s Hospital have started dosing the first patients in OPTIMAL‑e, a clinical trial bringing their next‑generation PSMA‑targeted radioligand therapy…
July 08, 2026
MAIA Biotechnology Reports 90.5% Disease Control Rate in Third-Line NSCLC from THIO-101 Part C Expansion Trial
MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on targeted immunotherapies for cancer, reported positive initial efficacy data on July 8, 2026…
Legend Biotech Corporation (NASDAQ: LEGN) achieved a major technological milestone on June 14, 2026, by establishing clinical proof-of-concept for its novel oncology asset, LB2501. The…
Tango Therapeutics Inc. (NASDAQ: TNGX) just delivered the kind of data that can reset a small‑cap oncology name, with shares soaring over 30% after new…
Aptevo Therapeutics Inc. (NASDAQ: APVO) and Niowave Inc. are forming a 50/50 partnership to develop up to three radiopharmaceutical cancer drugs, giving both companies a…